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Abstract 
Synchronous double malignancies of gastric carcinoma (GC) and malignant lymphoma 
(ML) are rare and very difficult to treat. We report a case of synchronous GC and nodal 
ML, regarding which clinical and pathological features and treatment are discussed. A 
68-year-old woman with a history of inguinal hernia was admitted for abdominal pain 
and high fever and subsequently underwent herniorrhaphy, but the fever remained. 
Computerized tomography showed a stomach mass and multiple enlarged lymph nodes 
in the abdominal cavity and inguinal regions. Gastric adenocarcinoma coexistent with 
advanced in situ follicular lymphoma was confirmed by endoscopy, biopsy of inguinal 
lymph nodes and bone marrow examination. Two chemotherapy regimens, R-CHOP 
(rituximab, cyclophosphamide, perarubicin, vincristine and prednisone) and systemic 
therapy (5-fluorouracil and calcium folinate) combined with regional perfusion 
(oxaliplatin and etoposide) through the left gastric artery were performed at intervals 
against ML and GC, respectively. Partial remission in both tumors was achieved after 4 
courses of treatment, but the patient finally died of heart failure. Scrupulous biopsy of 
non-draining lymph nodes in patients with gastrointestinal carcinomas is supposed to 
improve the diagnostic rate of simultaneous nodal ML. The interval chemotherapy 
strategy with two independent regimens is beneficial for such patients, especially for 
those unable to tolerate major surgery.  
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Introduction 
Double primary tumors including synchronous and metachronous ones are 
uncommon, but have been reported relatively more frequently in recent years. The 
coexistence of gastric carcinoma (GC) with gastric malignant lymphoma (ML) or gastric 
mucosa-associated lymphoid tissue (MALT) lymphoma is uncommon; therefore, careful 
endoscopy, sampling and pathological detection may improve the diagnostic accuracy [1, 
2]. Herein we present a very rare case of coexistent GC and nodal ML, the subtype of in 
situ follicular lymphoma (FL), which was effectively treated with interval chemotherapies 
including two different regimens. 
Case Report 
A 68-year-old woman with a 20-year history of a reducible right inguinal hernia was admitted to a 
basic hospital with complaints of abdominal pain for 40 hours and high intermittent fever for 1 month. 
The patient underwent herniorrhaphy but fatigue, high fever, abdominal distension, food reflux and 
loss of appetite remained. Computerized tomography of the abdomen indicated a mass in the lesser 
curvature of the stomach and multiple swollen lymph nodes in the peritoneal and retroperitoneal 
cavities. Then, the patient was transferred to our hospital. 
A physical examination showed splenomegaly, ascites, and many enlarged lymph nodes which were 
hard, not painful and of poor motion in bilateral inguinal areas. Laboratory tests revealed anemia 
(hemoglobin 68 g/l), thrombocytopenia (platelet count 67 × 10
9/l), and elevated serum levels of lactate 
dehydrogenase (LDH) (440 U/l; normal range 60–240 U/l), cancer antigens 125 (110.7 IU/ml; normal 
range <35.0 IU/ml) and 19-9 (49.6 IU/ml; normal range <37.0 IU/ml). Ascites were detected as reddish 
exudates with increased LDH (359 U/l) but normal cancer antigen levels, and some lymphoma cells and 
many monocytes confirmed by exfoliative cytologic examinations. Sputum and blood cultures were 
negative. On gastroscopy, a 4 × 3 cm mucosal zone of erosion and contact bleeding was observed below 
the cardia on the lesser curvature. Histopathological examination demonstrated that the lesion was a 
moderately differentiated adenocarcinoma accompanied by chronic gastritis (fig. 1), with positive 
detection of Helicobacter pylori using rapid urease test and Warthin-Starry stain. The specimen of the 
swollen inguinal lymph nodes histologically displayed an atypical hyperplasia of lymphoid follicles, 
being strongly diffusely positive for CD20, Bcl-2 and Pax-5 and scattered positive for CD3, CD5 and 
Ki67, but negative for CD10 and Bcl-6 by immunohistochemistry (fig. 2). Microscopical examination of 
bone marrow revealed lymphoid hyperplasia with about 13.5% of infiltrated lymphoma cells (fig. 3). 
The chromosome analysis exhibited an abnormal karyotype, 50,XX, +1, +3, +8, +18, 
del(22)(q?)[1]/46,XX[14]. Epstein-Barr virus (EBV) and EBV-encoded RNA were negative in both 
specimens of lymph nodes and gastric tissue by immunohistochemistry and in situ hybridization, 
respectively. As regards serum EBV-specific antibodies, anti-capsid antigen (CA) IgM was negative and 
anti-nuclear antigen-1 IgG was weakly positive, but anti-CA IgA, anti-CA IgG and anti-early antigen 
IgG were significantly positive and had dynamic changes within 6 months. EBV copy numbers were 
twice negatively determined in the serum by real-time polymerase chain reaction.  
The patient was finally diagnosed as GC coexisting with stage IVB nodal ML (in situ FL) and chronic 
gastritis, accompanied by present H. pylori infection and recent EBV infection. Stomach operation and 
biopsy of abdominal lymph nodes were not made because the patient had just undergone herniorrhaphy 
and could not tolerate them. The eradication therapy against H. pylori infection was made with 
rabeprazole (20 mg) daily and bismuth citrate (220 mg), tinidazole (500 mg), and clarithromycin (250 
mg) twice daily for 1 week. Furthermore, an R-CHOP regimen with rituximab (375 mg/m
2, day 1), 
cyclophosphamide (750 mg/m
2, day 2), perarubicin (40 mg/m
2, day 2), vincristine (1.4 mg/m
2, day 2), 
and prednisone (60 mg, days 2–6) was used to treat the ML. The intravenous therapy with 
5-fluorouracil (750 mg, days 1–5) and calcium folinate (200 mg, days 1–5), combining perfusion 
chemotherapy with oxaliplatin (150 mg, day 6) and etoposide (100 mg, day 6) through the left gastric 
artery, was performed against GC during intervals of R-CHOP. The patient reached partial remission in 
the two tumors after 4 courses of each regimen. However, severe thrombocytopenia delayed subsequent 
chemotherapies and she finally died of heart failure after discharge.  
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Discussion 
Synchronous malignancies of GC and nodal ML are very rare. One possible reason is 
that the enlargement of lymph nodes in a GC patient usually indicates lymphatic 
metastasis, which easily causes omission of further biopsy in order to reduce injury and 
discomfort. But in this case of GC, the unexplainable continuous high fever besides 
enlargement of non-draining lymph nodes was a key clue for successful diagnosis of 
simultaneous nodal ML, the second primary tumor. It is notable that the ML subtype in 
the present patient is considered very rare for in situ FL. The diagnosis was based on 
reliable evidence, including atypical hyperplasia of lymphoid follicles, strongly positive 
immunostains of CD20 and Bcl-2, and a relatively low level of Ki67 expression, although 
the immunophenotype is not common, with CD10 and Bcl-6 being negative [3, 4]. We 
presumed that this in situ FL patient might just have been in a specific transition stage 
from atypical hyperplasia to classical FL while being diagnosed, and therefore, typical 
phenotypes in biopsied lymph nodes were missing. 
Infections of H. pylori and EBV are possibly related with synchronous tumors, 
especially when both occur in the stomach. Nakamura et al. [1] described 10 patients with 
synchronous GC and gastric ML, in two of whom a simultaneous double infection with 
H. pylori and EBV was histopathologically confirmed in the stomach. As for H. pylori, it 
has been detected in over 50% of GC patients and in about 90% of gastric MALT 
lymphoma patients [5, 6]. Sakai et al. [7] even reported a 100% positivity rate for H. pylori 
in their 13 reviewed cases of synchronous adenocarcinoma and MALT lymphoma of the 
stomach. The tumor genesis processes of most GC and ML were postulated to be 
associated with chronic H. pylori gastritis, which was also found in our patient. Potential 
carcinogenic mechanisms of H. pylori are related with both host factors mainly meaning 
DNA damage, inadequate genetic repair and inflammatory reactions, and bacterial factors 
including cellular incorporation of H. pylori DNA and toxic effects of bacterial products, 
such as vacuolating toxin A, cytotoxin-associated gene A and ulcer-associated gene 
restriction endonuclease [8]. In addition, there was evidence that low-grade MALT 
lymphoma cells proliferated specifically dependent on T cell activation by H. pylori, which 
indicated key roles of H. pylori infection in the progression of lymphoid nodules to 
lymphoma [9]. Also, the gastric epithelium present inside a MALT lymphoma is 
susceptible to malignant transformation, owing to the presence of oncogenic factors, 
suppression of host immune functions, and the induction of autoimmune responses 
towards mimic H. pylori antigens, which may cause a further tissue injury and lead to 
simultaneous GC and lymphoma [10]. However, no reports, including our own, have 
confirmed a definite role of H. pylori in the pathogenesis of nodal FL. As for EBV, only a 
recent systemic infection was indicated but could not be linked to the double tumors in 
this case, although EBV is likewise thought to be involved in the development of the 
mentioned double malignancies [11–13]. Furthermore, the chromosome analysis in our 
patient suggested that gains in chromosomes 1, 3, 8, and 18 and the loss in 22q should be 
related with synchronous malignancies of GC and nodal ML, which needs confirmation 
in more cases. 
There are still no standard treatments for synchronous malignancies because of the 
rare occurrence. As for double tumors occurring in the stomach, the presence of 
adenocarcinoma usually determines the treatment modalities, which mainly include distal 
or total gastrectomy depending on the tumor localization, preoperative or postoperative 
chemotherapy, and radiotherapy [2]. If simultaneous lymphoma and carcinoma are 
correctly diagnosed, the gastrectomy will be the first-line choice referring to GC surgery 
principles. However, radical surgery for gastrointestinal lymphoma is now not often  
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suggested due to an increased additional morbidity for those with localized or residual 
disease or with certain complications [14–16]. Recently, Hamaloglu et al. [2] reviewed 25 
cases of synchronous gastric adenocarcinoma and lymphoma published with therapy 
information. There are 6 advanced-stage and 19 early-stage GC cases in the mentioned 
series, with median age being 68 (range 47–79) years and the majority of lymphoma types 
being MALT lymphoma. Twenty-four patients were treated with total or subtotal 
gastrectomy, 10 of whom were also subjected to radiotherapy and/or chemotherapy. Only 
1 case of synchronous early-stage adenocarcinoma and diffuse large-cell lymphoma was 
treated with chemotherapy and endoscopic mucosectomy. It is a pity that the data about 
the tumor size and survival time of these patients are not complete. As for synchronous 
GC and non-gastric ML (such as nodal FL in this case), reports are rare and no consensus 
on management principles exists. Surgery and systemic chemotherapy are basic 
treatments for GC and nodal ML, respectively [2]. Nevertheless, in this special patient 
with poor performance status, any aggressive surgery may increase risk of death even 
compared with best supportive care. Interval chemotherapies with two regimens 
containing systemic plus regional use of 5-fluorouracil, oxaliplatin and etoposide against 
GC and classical R-CHOP against CD20-positive ML were therefore chosen to treat the 
coexisting malignancies and actually brought about a survival gain. 
To our knowledge, this is the first case of synchronous primary GC and nodal ML 
encountered in the English literature. Our case suggested that a scrupulous biopsy of the 
non-draining lymph nodes in patients with gastrointestinal carcinomas, with or without B 
symptoms of ML, is supposed to improve the diagnostic rate of related double primary 
tumors. The interval chemotherapy strategy with double regimens targeting different 
tumors that we adopted may be one of the prospective choices for some patients, 
especially those with poor performance status.  
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Fig. 1. Moderately differentiated adenocarcinoma of the stomach, accompanied by chronic gastritis 
(HE, ×20). 
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Fig. 2. Inguinal lymph node sections showing a rare in situ follicular lymphoma (a HE, ×40; b HE, 
×200) with the special immunophenotype containing positive Bcl-2 (c ×40, d ×200), Pax-5 (e ×40, 
f ×400), CD20 (g ×400) and Ki67 (h ×200), but negative CD10 (i ×100) and Bcl-6 (j ×400). 
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Fig. 3. Bone marrow examination showing lymphoid hyperplasia with infiltrated lymphoma cells 
(Giemsa staining, ×1,000). 
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